Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone

✍ Scribed by Emilio Montserrat; Antonio Alcalá; Ricardo Parody; Andreu Domingo; Javier García-Conde; Javier Bueno; Carmen Ferrán; Miguel A. Sanz; Manuel Giralt; Daniel Rubio; Isabel Antón; Jordi Estapé; Ciril Rozman; Participating members of pethema: Spanish Cooperative group for hematological malignancies treatment; Spanish society of hematology

• Publisher: John Wiley and Sons
• Year: 1985
• Tongue: English
• Weight: 685 KB
• Volume: 56
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19851115)56:10<2369::aid-cncr2820561004>3.0.co;2-n

✦ Synopsis

Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0.4 mg/kg orally, day 6) plus prednime (PDN) (60 mg/m2 orally, days 1-5) every 2 weeks or cyclophosphamide (600 mg/m' intravenously, day 6A vincristiw (1 mg/m* intravenously, day 6A and prednisone (60 mg/m2 orally, days 1-5) (COP) each moath for 5 months. Complete remissloo (CR) was defined as the total disappearance of signs and symptoms related to the disease. Partial remission (PR) was considered to be achieved when, after treatment, the clinical stage changed to a less advanced one. Thirty (59%) responses (8% CR) with CLR plus PDN and 14 (31%, 2% CR) with COP were observed (P < 0.01). The survival was not significantly different for the two groups. Patients previously treated had a lower number of responses (11/35, 31%) than those with no previous treatment (33/61, 54%) (P < 0.05). Patients who attained a CR or a goad PR had longer survivals (median not reached) than those with a poor PR (median, 25.2 months) or those who did not respond to treatment (median, 11.5 months) (P < 0.005).